Found: 5
Select item for more details and to access through your institution.
A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN'S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 136, doi. 10.1093/jcag/gwz006.067
- By:
- Publication type:
- Article
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 1, p. 50, doi. 10.1111/apt.13838
- By:
- Publication type:
- Article
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 9, p. 1082, doi. 10.1111/apt.13387
- By:
- Publication type:
- Article
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 5, p. 486, doi. 10.1111/apt.12863
- By:
- Publication type:
- Article
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 10, p. 1236, doi. 10.1111/apt.12499
- By:
- Publication type:
- Article